References

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376.
2. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life) (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376.
3. Adamson S (1985) Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogenic Substances. San Francisco: Four Trees Publications.
4. Aghajanian GK, Lieberman JA (2001) Response. Neuropsychopharmacol 24:335-336.
5. Alting Von Geusau N, Stalenhoef, P, Huizinga M, Snel J, Ridderinkhof KR (2004) Impaired executive function in male MDMA (Ecstasy) users. Psychopharmacology (Berl), Published online March 18, 2004. DOI: 10.1007/s00213-004-1832-8.
6. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington DC: American Psychiatric Association Press.
7. Anonymous (1999) Series of letters on MDMA and cancer. MAPS Bulletin 9(1):56-59.
8. Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S, Rodes J (1998) Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 29: 394-397.
9. Arnsten AF (1998) The biology of being frazzled. Science 280: 1711-1712. Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE (2003) Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in recreational users. Clin Neuropsychol 17:446-459.
10. Baggott M (2002) Preventing problems in ecstasy users; Reduce use to reduce harm. J Psychoactive Drugs 34:145-162.
11. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills JAMA 284:2190.
12. Baggott M, Mendelson J (2001) Does MDMA cause brain damage? In Holland J (Ed), Ecstasy, A Complete Guide. Rochester VT: Inner Tradition, 110-145.
13. Battaglia G, Yeh SY, De Souza EB (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29: 269-274.
14. Beardsley PM, Balster RL, Harris LS (1986) Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18: 149-157.
15. Beck AT, Steer RA (1988) Manual for the Beck Hopelessness Scale. New York: Psychological Corporation.
16. Beck A, Weissman A, Lester D, Trexler L (1974) The measurement of pessimism: the Beck Hopelessness Scale. J Consult Clin Psychol 42:861-865.
17. Beitia G, Cobreros A, Sainz L, Cenarruzabeitia E (2000) Ecstasy-induced toxicity in rat liver. Liver 20: 8-15.
18. Bhattachary S, Powell JH (2001) Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': Evidence for cognitive impairment. Psychological Med 31:647-658.
19. Bilsky EJ, Hui YZ, Hubbell CL, Reid LD (1990) Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. Pharmacol Biochem Behav 37: 633-8,
20. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51:1532-1537.
21. Bond AJ, Verheyden SL, Wingrove J, Curran HV (2004) Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacol (Berl) 171:331-339.
22. Bonny HL, Savary LM (1990) Music and Your Mind. Tarrytown NY: Station Hill.
23. Boone KB, Chang L, Grob CS, Poland RE (unpublished, in preparation) Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) Unpublished data, presented on p. 24-25 in the Investigator's Brochure.
24. Bouso JC (2004) Personal communication to Rick Doblin PhD and Lisa Jerome PhD., January 15, 2003.
25. Bouso JC (2001) Using MDMA in the treatment of posttraumatic stress disorder. In Holland J (Ed), Ecstasy, A Complete Guide. Rochester VT: Inner Traditions, 248-260.
26. Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD, Ali SF, Frederick DL, Paule MG (2003) Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicol 24:379-390.
27. Brady JF, Di Stefano EW, Cho AK (1986) Spectral and inhibitory interactions of (+/-)- 3,4-methylenedioxyamphetamine (MDA) and (+/-)-3,4- methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes. Life Sci 39: 1457-1464.
28. Brady M, Peterman A, Fitchett G, Mo M, Cella D (1999) A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology 8:417-428.
29. Breitbart W, Rosenfeld B, Pessin H, Pessin H, Kaim M, Funesti-Esch J, Galietta M, Nelson CJ, Brescia R (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284:2907-2911.
30. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV (2003) 3,4- Methylenedioxymethamphetamine (Ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228-3235.
31. Brown PL, Kiyatkin EA. (2004) Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci. 20:51-58.
32. Brunner D, Hen R (1997) Insights into the neurobioloserotonin receptor knockout mice. Ann N Y Acad Sci 836: 81-105.
33. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M (2003) Long-term effects of "Ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44:375-384.
34. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M. (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161:1181-1189.
35. Caballero F, Lopez-Navidad A, Cotorruelo J, Txoperena G (2002) Ecstasy-induced brain death and acute hepatocellular failure: multiorgan donor and liver transplantation. Transplantation 74: 532-537.
36. Callahan BT, Cord BJ, Ricaurte GA (2001). Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40: 113-121.
37. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466.
38. Carvalho M, Carvalho F, Bastos ML (2001) Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4- methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch Toxicol 74:789-793.
39. Carvalho M, Carvalho F, Remiao F, de Lourdes Pereira M, Pires-Das-Neves R, de Lourdes Bastos M (2002) Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76: 166-172.
40. Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, Monks TJ, Carvalho F, Bastos ML. (2003) Hepatotoxicity of 3,4- methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 78:16-24.
41. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002a) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547-561.
42. Cella D, Nowinski CJ (2002b) Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 83(12 Suppl 2):S10-S17.
43. Chang L, Ernst T, Grob CS, Poland RE (1999) Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users. J Magn Reson Imaging 10: 521-526.
44. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98:15-28.
45. Chite T, McCormick C (1999) Memorandum of telecom meeting minutes for meeting between FDA and MAPS, communication to Rick Doblin; July 23, 1999.
46. Cho AK, Hiramatsu M, Distefano EW, Chang AS, Jenden DJ (1990) Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab Dispos 18: 686-691.
47. Chu T, Kumagai Y, DiStefano EW, Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51: 789-796.
48. Clark CR, Geffen GM, Geffen LB (1987) Catecholamines and attention. II: Pharmacological studies in normal humans. Neurosci Biobehav Rev 11: 353-364.
49. Cole JC, Sumnall HR, O'Shea E, Marsden CA (2003) Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology (Berl) 166:383-390.
50. Cole JC, Sumnall HR (2003a) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98:35-58.
51. Cole JC, Sumnall HR (2003b) The pre-clinical behavioural pharmacology of 3,4- methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199-217.
52. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338-345.
53. Connor TJ, Kelly JP, Leonard BE (2000a) An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats. Immunopharmacology 46: 223-235.
54. Connor TJ, Kelly JP, McGee M, Leonard BE (2000b) Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1beta and TNF-alpha secretion following an in vivo lipopolysaccharide challenge. Life Sci 67: 1601-1612.
55. Connor TJ, Harkin A, Kelly JP. (2004) Methylenedioxymethamphetamine (MDMA; "Ecstasy") suppresses production of the pro-inflammatory cytokine tumor necrosis factor-{alpha} independent of a {beta}-adrenoceptor-mediated increase in interleukin-10. J Pharmacol Exp Ther.2004 Published on-lineAug 26 2004.
56. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS. (2003) Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482: 339-341.
57. Cottler L, Womack SB, Compton WM, Ben-Abdallah A (2001). Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Human Psychopharmacology, Clinical and Experimental, 16; 599-606.
58. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim MJ, Hwang J, Haga E, Vimal RL, Lukas SE, Renshaw PF (2003) Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 72: 225-235.
59. Cozzi NV, Sievert MK, Shulgin AT, Jacob P, 3rd, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381: 63-69.
60. Crifasi J, Long C (1996) Traffic fatality related to the use of methylenedioxymethamphetamine. J Forensic Sci 41: 1082-1084.
61. Curran HV, Verheyden SL (2003) Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacol (Berl) 169:91-103.
62. Dafters RI, Hoshi R, Talbot AC (2004) Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacol (Berl) 173: 405-410.
63. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 16 :627-633.
64. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self- reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacol (Berl) 173 :398-404.
65. de Boer D, Tan LP, Gorter P, van de Wal RM, Kettenes-van den Bosch JJ, de Bruijn EA, Maes RA (1997) Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry. J Mass Spectrom 32: 1236-1246.
66. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000a) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
67. de la Torre R, Farre M, Roset PN, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000b) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914: 225-237.
68. de la Torre R, Farre M. (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci. 25: 505-508.
69. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J. (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 26: 137-144.
70. Delaforge M, Jaouen M, Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome p450: particular involvement of CYP 2D. Environmental Toxicology and Pharmacology 7:153-158.
71. De Win MM, Reneman L, Reitsma JB, Den Heeten GJ, Booij J, Van Den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 173: 376-382.
72. Derogatis LR (1994) SCL-90-R: Administration, Scoring and Procedures Manual. National Computer Systems, Inc., Minneapolis.
73. Doblin R (2002) A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA. J Psychoactive Drugs 34:185-194. d'Otalora, M (2004) MDMA and LSD Therapy in the Treatment of Post Traumatic Stress Disorder in a Case of Sexual Abuse. http://www.maps.org/research/mdma/moaccount.html
74. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18:335-340.
75. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3, 4- methylenedioxymethamphetamine (Ecstasy) in humans [published erratum appears in Clin Chem 45(9):1585]. Clin Chem 45: 1058-1069,
76. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4- Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) 161: 356-364.
77. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH (2003) Pharmacological characterization of the effects of 3,4- methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166: 202-211.
78. Fantegrossi WE, Kiessel CL, Leach PT, Martin CV, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH. (2004a) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) 173:270-277.
79. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G. (2004b) Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys. Neuropsychopharmacology. Published electronically Feb 16 2004
80. Farre M, De La Torre R, O Mathuna B, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:3 64-375.
81. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci 15: 5476-5485.
82. Fitzgerald RL, Blanke RV, Poklis A (1990) Stereoselective pharmacokinetics of 3,4- methylenedioxymethamphetamine in the rat. Chirality 2: 241-248.
83. Fitzgerald JL, Reid JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191: 217-220.
84. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 4/97 Revision). New York; Biometrics Research Department, New York State Psychiatric Institute.
85. Folstein M, Folstein S, McHugh P (1975) Mini-mental state": a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
86. Fornai F, Lenzi P, Frenzilli G, Gesi M, Ferrucci M, Lazzeri G, Biagioni F, Nigro M, Falleni A, Giusiani M, Pellegrini A, Blandini F, Ruggieri S, Paparelli A. (2004) DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berl) 173:353-363.
87. Forsling M, Fallon JA, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4- methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor? J Pharmacy Pharmacol 53: 1357-1363.
88. Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, Sahakian BJ (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology (Berl) 162:203-214.
89. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX (2001)Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Hum Brain Mapp 14: 152-165.
90. Friedman HL (1983) The Self-Expansiveness Level Form: A conceptualization and measurement of a transpersonal construct. J Transpersonal Psychology 15:37-50. Gasser P (1994) Psycholytic Therapy with MDMA and LSD in Switzerland. MAPS Newsletter 5(3):3-7.
91. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F (2000) Long-lasting effects of (+/-)3,4- methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47:127-136.
92. Gerra G, Zaimovic A, Ampollini R, Giusti F, Delsignore R, Raggi MA, Laviola G, Macchia T, Brambilla F (2001) Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine ("Ecstasy") use history: psychobiological correlates. J Subst Abuse 13:471-491.
93. Gijsman HJ, Verkes RJ, van Gerven JM, Cohen AF (1999) MDMA study (Letter to the Editor). Neuropsychopharmacol 21:597.
94. Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, Leakey JE, Kolta M, Slikker W, Jr. (1989) Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10: 455-466.
95. Gore SM (1999) Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet 354:1265-1266.
96. Gouzoulis-Mayfrank, E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68:719-725.
97. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hansen G, Daumann J (2003) Memory impairments suggest hippocampal dysfunction in abstinent Ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27:819-827.
98. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54: 129-141.
99. Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M (2003) Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21:121-124.
100. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacol (Berl) 119:247-260.
101. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI. (2004) Effect of ambient temperature and a prior neurotoxic dose of 3,4- methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology (Berl) 173:264-269.
102. Greer G, Tolbert RA (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18:319-327.
103. Greer GR, Tolbert R (1998) A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 30:371-379.
104. Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40:393-404.
105. Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4- methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73:103-107.
106. Grob CS, Poland RE, Boone KB (unpublished) Psychological, physiological and neuroendocrine effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in healthy humans. Data presented in Investigators' Brochure.
107. Grof S (1980) LSD Psychotherapy. Alameda CA: Hunter House.
108. Grof S (2000) The Psychology of the Future. Albany: SUNY Press.
109. Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4- methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66: 243-249.
110. Guimaraes FS, Del Bel EA, Padovan CM, Netto SM, de Almeida RT (1993) Hippocampal 5-HT receptors and consolidation of stressful memories. Behav Brain Res 58: 133-139.
111. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JH, Yurgelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135-147. DOI: 10.1016/k/drugalcdep.2004.02.008.
112. Hamilton, M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
113. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-61.
114. Hamilton M (1967) Development of a rating scale; for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
115. Hanson KL and Luciana M (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34: 229-246.
116. Harmon RJ, Riggs PD (1996) Clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 35: 1247-1249.
117. Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacol (Berl) 162: 396-405.
118. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
119. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539-553.
120. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20: 432-440.
121. Helmlin HJ, Brenneisen R (1992) Determination of psychotropic phenylalkylamine derivatives in biological matrices by high-performance liquid chromatography with photodiode-array detection. J Chromatogr 593: 87-94.
122. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M (1998) Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet 351: 1784.
123. Henry JA, Rella JG (2001) Medical risks associated with MDMA use. In Holland J (Ed). Ecstasy, A Complete Guide. Rochester VT: Inner Traditions, 71-86.
124. Hensley D, Cody JT (1999) Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS. J Anal Toxicol 23: 518-523.
125. Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-244.
126. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A. (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32: 1213-1217.
127. Hiramatsu M, Cho AK (1990) Enantiomeric differences in the effects of 3,4- methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29: 269-275.
128. Hiramatsu M, Kumagai Y, Unger SE, Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254: 521-527.
129. Holland J (Ed) (2001) Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester VT: Inner Traditions.
130. House RV, Thomas PT, Bhargava HN (1995) Selective modulation of immune function resulting from in vitro exposure to methylenedioxymethamphetamine (Ecstasy). Toxicology 96: 59-69.
131. Jansen KL (1999. Ecstasy (MDMA) dependence Drug Alcohol Depend 53:121-124. Johnson EA, Shvedova AA, Kisin E, O'Callaghan JP, Kommineni C, Miller DB (2002) d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res 933: 150-63.
132. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T (1998) The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59: 1003-1009.
133. Karnofsky D, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C (Ed) Evaluation of chemotherapeutic agents. New York: Columbia University Press, 191-205.
134. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ (2002) Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137: 963-970.
135. Kinzie JD, Leung P (1989) Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 177: 546-550.
136. Koch S, Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104: 135-146
137. Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. (2003A) Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol 25: 509-517.
138. Koprich JB, Campbell NG, Lipton JW. (2003B) Neonatal 3,4- methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Res Dev Brain Res Dec 147: 177-182.
139. Kraemer T, Maurer HH (2002) Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24:277-289. Kreth K, Kovar K, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59: 1563-1571.
140. Kumagai Y, Wickham KA, Schmitz DA, Cho AK (1991) Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Participation of different cytochrome P450 isozymes in the demethylenation reaction. Biochem Pharmacol 42: 1061-1067.
141. Lamb RJ, Griffiths RR (1987) Self-injection of d,1-3,4- methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) 91: 268-272.
142. Lamers CTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 17:379-387.
143. Lanz M, Brenneisen R, Thormann W (1997) Enantioselective determination of 3,4- methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis 18: 1035-1043.
144. Lavelle A, Honner V, Docherty JR (1999) Investigation of the prejunctional alpha2- adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 128: 975-980.
145. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 133: 969-973.
146. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68:195-207.
147. Lieberman JA, Aghajanian GK (1999) Caveat emptor: Researcher beware. Neuropsychopharmacol 21:471-473.
148. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol 22:513-521.
149. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000b) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacol 23:396-404.
150. Liechti ME, Gamma A, Vollenweider FX (2001a) Gender differences in the subjective effects of MDMA. Psychopharmacol 154:161-168.
151. Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001b) Effects of MDMA (Ecstasy) on pre-pulse inhibition and habituation of startle in humans after pretreatment with citalopam, haloperidol, or ketanserin. Neuropsychopharmacol 24:240-252.
152. Liechti ME, Vollenweider FX (2000a) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10:289-295.
153. Liechti ME, Vollenweider FX (2000b) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4- methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274.
154. Lim HK, Foltz RL (1988) In vivo and in vitro metabolism of 3,4- (methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol 1: 370-378.
155. Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in health humans. Biol Psychiatry 53 (Suppl); 205S. Data presented at the 58th Annual Conference of the Society for Biological Psychiatry, San Francisco, CA.
156. MacPherson RD (2002) New directions in pain management. Drugs of Today 38:135-145.
157. Mahmood I, Balian JD (1996) Interspecies scaling; A comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579-585.
158. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145.
159. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113: 133-142.
160. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
161. McCann U, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in 3,4- methylenedioxymethamphetamine (MDMA) users: A controlled study. Psychopharmacol 143:417-425.
162. McCann UD, Ricaurte G (2001) Caveat emptor: Editors beware. Neuropsychopharmacol 24:333-334.
163. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH (1999) Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-1442.
164. McClain CS, Rosenfeld B, Breitbart W (2003) Effect of spiritual well-being on end-of- life despair in terminally ill cancer patients. Lancet 361: 1603-1607.
165. Metzner R, Adamson S (2001) Using MDMA in Healing, Psychotherapy and Spiritual Practice. In Holland J (Ed), Ecstasy, A Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Inner Traditions: 182-207. Originally published in ReVision 10(4) (1988) The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice.
166. Meyer A, Mayerhofer A, Kovar KA, Schmidt WJ. (2002) Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4- methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats. Neurosci Lett 330: 280-284.
167. Miller DB, O'Callaghan JP (1996) Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interactions with stress and the adrenal system. Ann N Y Acad Sci 801:148-167.
168. Mills EM, Banks ML, Sprague JE, Finkel T. (2003) Pharmacology: uncoupling the agony from ecstasy. Nature 426: 403-404.
169. Mithoefer M (2004a) Personal communication to Rick Doblin PhD and Lisa Jerome PhD; Electronic e-mail sent November 4, 2004.
170. Mithoefer M (2004b) Personal communication to Rick Doblin; Electronic mail sent Nov 12, 2004.
171. Mithoefer M (2004c) MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder; a fourth update on the approval process and first report on study progress. MAPS Bulletin 14(1): 3-4.
172. Mithoefer M, Wagner M (2001) a human phase II study - Safety and efficacy of 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of chronic posttraumatic stress disorder (PTSD). Protocol submitted to the Food and Drug Administration, October 2001. IND #63,384.
173. Montiel-Duarte C, Varela-Rey M, Oses-Prieto J, Lopez-Zabalza M, Beitia G, Cenarruzabeitia E, Iraburu M (2002) 3,4-Methylenedioxymethamphetamine ("Ecstasy") induces apoptosis of cultured rat liver cells. Biochim Biophys Acta 1588: 26-32.
174. Moore KA, Mozayani A, Fierro MF, Poklis A (1996) Distribution of 3,4- methylenedioxymethamphetamine (MDMA) and 3,4- methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci Int 83: 111-119.
175. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacol (Berl) 141: 30-36.
176. Naranjo C (2001) Experience with the interpersonal psychedelics. In Holland J (Ed), Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Inner Traditions, 208-221.
177. Nash JF, Brodkin J (1991) Microdialysis studies on 3,4- methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259: 820-825.
178. Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177: 111-115.
179. Navarro, M, Pichini, S, Farre, M, Ortuno, J, Roset, PN, Segura, J, de la Torre, R (2001). Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine References and its metabolites: Correlation with plasma drug concentrations and effect of salivary pH. Clinical Chemistry, 47: 1788-1795.
180. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18: 305-313.
181. Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: A new class of psychoactive agents? In Peroutka SJ (Ed), Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Holland: Kluwer.
182. Obergriesser T, Ende G, Braus DF, Henn FA (2001) Hippocampal [1H]-MRSI in ecstasy users. European Archives of Psychiatry and Clin Neurosci 251: 114-116.
183. O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
184. Office of Applied Studies, Substance Abuse and Mental Health Services Administration. (2003). Results from the 2002 National Survey on Drug Use and Health: Detailed tables available online http://www.oas.samhsa.gov/nhsda/2k2nsduh/html/Sect1peTabs1to110A.htm#tab1.1a.
185. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803.
186. Ortuno J, Pizarro N, Farre M, Mas M, Segura J, Cami J, Brenneisen R, de la Torre R (1999) Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 723: 221-232.
187. Ohnhaus EE, Adler R (1975) Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1: 379-384.
188. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65: L309-L316.
189. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Hernandez Lopez C, Ortuno J, Segura J, Cami J, de la Torre R (2000) Immunomodulating activity of MDMA. Ann N Y Acad Sci 914: 215-224.
190. Pacifici R, Zuccaro P, Lopez CH, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, Torre RL (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296: 207-215.
191. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuno J, Menoyo E, Segura J, de la Torre R (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965: 421-433.
192. Pacifici R, Pichini S, Zuccaro P, Farre M, Segura M, Ortuno J, Di Carlo S, Bacosi A, Roset P, Segura J, De La Torre R (2004) Paroxetine inhibits acute effects of MDMA on the immune system in humans. J Pharmacol Exp Ther 309: 285-292.
193. Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P, Gittos MW, Carr AA (1993) Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology (Berl) 112: S60-S67.
194. Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D (2002) Measuring spiritual well-being in individuals with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 24:49-58.
195. Pedersen W, Skrondal A (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction 94: 1695-1706.
196. Pichini S, Navarro M, Farre M, Ortuno J, Roset PN, Pacifici R, Zuccaro P, Segura J, de la Torre R (2002) On-site testing of 3,4-methylenedioxymethamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users. Clin Chem 48:174-176.
197. Pichini S, Navarro M, Pacifici R, Zuccaro P, Ortuno J, Farre M, Roset PN, Segura J, de la Torre R (2003) Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J Anal Toxicol 27:294-303.
198. Pizarro N, Ortuno J, Farre M, Hernandez-Lopez C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, Cami J, de la Torre R (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
199. Pizarro N, Llebaria A, Cano S, Joglar J, Farre M, Segura J, de la Torre R (2003) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 17:330-336.
200. Pizarro N, Farre M, Pujadas M, Peiro AM, Roset PN, Joglar J, de la Torre R. (2004) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4- dihydroxymethamphetamine). Drug Metab Dispos 32:1001-1007.
201. Portenoy R, Thaler H, Kornblith A, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The Memorial Symptom Assessment Scale: an instrument for evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326-1336.
202. Potter VT, Wiseman CE, Dunn SM, Boyle FM (2003) Patient barriers to optimal cancer pain control. Psycho-Oncology 12: 153-160.
203. Ramcharan S, Meenhorst PL, Otten JM, Koks CH, de Boer D, Maes RA, Beijnen JH (1998) Survival after massive ecstasy overdose. J Toxicol Clin Toxicol 36: 727-731.
204. Randall-David E, Wright J, Porterfield DS, Lesser G (2003) Barriers to cancer pain management: home-health and hospice nurses and patients. Supportive Care Cancer 11:660-665.
205. Reneman L, Booij K, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet
206. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297:2260-2263.
207. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2003) Retraction. Science 301:1479.
208. Ricaurte GA (2004) Grant Progress Report. Obtained via Freedom of Information Act (FOIA) Request on January 16, 2004. Link: http://www.maps.org/mdma/retraction/foia012804/progress1.hml.
209. Ritz MC, Kuhar MJ (1993) Psychostimulant drugs and a dopamine hypothesis regarding addiction: update on recent research. Biochem Soc Symp 59: 51-64.
210. Robbins TW, Everitt BJ (2000) Central Norepinephrine Neurons and Behavior Psychopharmacology, The Fourth Generation of Progress On-Line Edition. The American College of Neuropsychopharmacology.
211. Robertson AR (1997) Fluoxetine and involuntary recall of remote memories. Aust N Z J Psychiatry 31: 128-130.
212. Robledo P, Balerio G, Berrendero F, Maldonado R. (2004) Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 369:338-349.
213. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy." Psychopharmacol (Berl) 151:19-24.
214. Rohrig TP, Prouty RW (1992) Tissue distribution of methylenedioxymethamphetamine. J Anal Toxicol 16: 52-53.
215. Rosenfeld B, Breitbart W, Stein K, Funesti-Esch J, Kaim M, Krivo S, Galietta M (1999). Measuring desire for death among patients with HIV/AIDS: the Schedule of Attitudes Toward Hastened Death. Am J Psychiatry 156:94-100.
216. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
217. Rothman R, Baumann M (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95: 73-88.
218. Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4- methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89: 1817-1821.
219. Ruse J, Jerome L, Mithoefer M, Doblin R (2002) MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder (PTSD): A Treatment Manual Draft. MAPS.
220. Ruse J, Jerome L, Halpern JH, Doblin R (2004) MDMA-Assisted Psychotherapy for the Treatment of Anxiety Associated with a Diagnosis of Advanced Stage Cancer: A Treatment Manual Draft. MAPS.
221. Sabol KE, Lew R, Richards JB, Vosmer GL, Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 276:846-854.
222. Samyn N, De Boeck G, Wood M, Lamers C, De Waard D, Brookhuis K, Verstraete A, Riedel W (2002) Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 128: 90-97.
223. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain. Synapse 29: 183-192.
224. Schenk S, Gittings D, Johnstone M, Daniela E (2003) Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169: 21-27.
225. Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (1992) 5-HT2 receptors exert a state- dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223: 65-74.
226. Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974: 127-133. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G (1993) Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 44: 1227-31,
227. Seiden LS, Kleven MS (1989) Methamphetamine and related drugs: toxicity and resulting behavioral changes in response to pharmacological probes. NIDA Res Monogr 94:146-160.
228. Seiden LS, Sabol KE (1996) Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 163:251-276.
229. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, de La Torre R (2001) Links 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208.
230. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63: 1223-1229.
231. Shulgin AT (1990) History of MDMA. In SJ Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Boston: Kluwer Academic Publishers.
232. Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds.) The Pharmacology of Hallucinogens. New York: Pergamon.
233. Shvartzman P, Friger M, Shani A, Barak F, Yoram C, Singer Y (2003) Pain control in ambulatory cancer patients--can we do better? J Pain Symptom Management 26:716-722.
234. Simantov R, Tauber M (1997) The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. Faseb J 11: 141-146.
235. Simon NG, Mattick RP (2002) The impact of regular Ecstasy use on memory function. Addiction 97:1523-1529.
236. Spielberger CS, Gorsuch RL, Lushene RE (1970) Manual for the State Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
237. Sprague JE, Banks ML, Cook VJ, Mills EM. (2003) Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4- methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305: 159-166.
238. Stevens S (1997) Speaking the silence: MDMA in a couple dealing with cancer. MAPS Bulletin 7(4):6-10.
239. Stevens S (1999) MDMA in a couple struggling with cancer: Two years later. MAPS Bulletin 9(3):15-17.
240. Stevens S (2000) MDMA and a couple struggling with cancer: Sue's final letter. MAPS Bulletin 9(4):31-34.
241. Stolaroff M (1997) The Secret Chief: Conversations with a pioneer of the underground therapy movement. Sarasota FL: Multidisciplinary Association for Psychedelic Studies.
242. Stumm G, Schlegel J, Schafer T, Wurz C, Mennel HD, Krieg JC, Vedder H (1999) Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. Faseb J 13: 1065-1072.
243. Tancer, ME (2003) Personal communication to L Jerome, January 17, 2003.
244. Tancer ME, Johnson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65: 97-101.
245. Tancer M, Johanson C-E (2003) Reinforcing, subjective and physiological effects of MDMA in humans; A comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33-44.
246. Tancer ME, Johanson C-E, Freedman RR (2003) MDMA elevates core temperature in warm and cold conditions in man. Poster presented at College of Problems of Drug Dependence Conference, Miami, FL. CPDD Abstracts,
247. Tancer ME, Johanso C-E (2004) The effects of fluoxetine response to MDMA, mCPP nad d-amphetamine in humans. Poster presented at College on Problems of Drug Dependence Conference, San Juan, Puerto Rico, CPDD Abstracts.
248. Thomas JR, von Gunten CF (2003) Pain in terminally ill patients: guidelines for pharmacological management. CNS Drugs 17: 621-631.
249. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacol (Berl) 167:85-96.
250. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-15.
251. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
252. Unkefer RF (1990) Music Therapy in the Treatment of Adults with Mental Disorders: Theoretical Bases and Clinical Interventions. New York: Schirmer Books. Van Dyke C, Stesin A, Jones R, Chuntharapai A, Seaman W (1986) Cocaine increases natural killer cell activity. J Clin Invest 77:1387-1390.
253. Varela-Rey M, Montiel-Duarte C, Beitia G, Cenarruzabeitia E, Iraburu MJ (1999) 3,4- methylenedioxymethamphetamine ("Ecstasy") stimulates the expression of alpha1(I) procollagen mRNA in hepatic stellate cells. Biochem Biophys Res Commun 259: 678-682.
254. Vollenweider FX (2001) Letter of support for IND #63,384; pp. 189-190 in Mithoefer M, Wagner M IND #63,384.
255. Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA- naive healthy volunteers. Neuropsychopharmacol 19:241-251.
256. Vollenweider FX, Gamma A, Liechti M, Huber T (1999a) Is a single dose of MDMA harmless? Neuropsychopharmacol 21:598-600.
257. Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999b) Opposite effects of 3,4- methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology (Berl) 143: 365-372.
258. Vollenweider FX, Gucker P, Schonbachler R, Kamber E, Vollenweider-Scherpenhuyzen MFI, Schubiger G, Hell D (2000) Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Der Nervenarzt 71 (Suppl 1) 534.
259. Vollenweider FX, Jones RT, Baggott MJ (2001) Caveat emptor: editors beware. Neuropsychopharmacol 24:461-462.
260. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. (2002) Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend. 66:147-159.
261. Wakonigg G, Sturm K, Saria A, Zernig G. (2003) Methylenedioxymethamphetamine (MDMA, 'ecstasy') serves as a robust positive reinforcer in a rat runway procedure. Pharmacology 69:180-182.
262. Wang X, Baumann MH, Xu H, Rothman RB. (2004) 3,4- methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53:240-248.
263. Wareing M, Fisk J, Murphy PN (2000) Working memory deficits in current and previous users of MDMA ("Ecstasy"). Br J Psychol 91:181-188.
264. Wareing M, Murphy PN, Fisk JE (2004) Visuospatial memory impairments in users of MDMA ("Ecstasy") Psychopharmacol (Berl) 173: 391-397.
265. Wells N, Hepworth JT, Murphy BA, Wujcik D, Johnson R (2003) Improving cancer pain management through patient and family education. J Pain Symptom Management 25: 344-356.
266. Widmer S (1998) Listening into the heart of things: The awakening of love: On MDMA and LSD: The undesired psychotherapy. Gerolfingen, Switzerland: Basic Editions.
267. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV (2003) Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968: 89-101.
268. Wise RA & Bozarth MA (1985) Brain mechanisms of drug reward and euphoria. Psychiatr Med 3: 445-460.
269. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53: 1605-1612.
270. Yamamoto BK, Nash JF, Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273: 1063-1070.
271. Zakzanis KK, Young DA (2001a) Memory impairment in abstinent MDMA ("ecstasy") users: A longitudinal investigation. Neurology 56: 966-969.
272. Zakzanis KK, Young DA (2001b) Executive function in abstinent MDMA ("ecstasy") users. Med Sci Monitor 7: 1292-1298.